Cargando…

High expression of survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin

Lack of effective biomarkers is one of the challenges in current neoadjuvant chemotherapy to predict drug response and sensitivity of cervical squamous cell carcinoma (CSCC). The present study was designed to investigate the correlation of the expression of survivin, an inhibitor of apoptosis with t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yunzhong, Yan, Hong, Li, Ruiping, Guo, Yuzhen, Zheng, Rongfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531053/ https://www.ncbi.nlm.nih.gov/pubmed/31096466 http://dx.doi.org/10.1097/MD.0000000000015607

Ejemplares similares

Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma
por: Yan, Li, et al.
Publicado: (2020)

Co-expression of VEGF-C and survivin predicts poor prognosis in esophageal squamous cell carcinoma
por: Zeng, Yun-Zhu, et al.
Publicado: (2021)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

High expression of HSP60 and survivin predicts poor prognosis for oral squamous cell carcinoma patients
por: Zhou, Ying, et al.
Publicado: (2023)

Chemoradiation with Weekly Paclitaxel and Carboplatin in Esophageal Squamous Cell Carcinoma: A Prospective Study
por: Joseph, Deepa M., et al.
Publicado: (2021)

A Case of Metastatic Basosquamous Basal Cell Carcinoma Treated With Carboplatin and Paclitaxel
por: Papageorgiou, Chryssoula, et al.
Publicado: (2023)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2017)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
por: Yang, Jin-Ji, et al.
Publicado: (2014)

Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis
por: Zhang, Li, et al.
Publicado: (2020)

Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2018)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas, Michael, et al.
Publicado: (2017)

OCT4 Positively Regulates Survivin Expression to Promote Cancer Cell Proliferation and Leads to Poor Prognosis in Esophageal Squamous Cell Carcinoma
por: Li, Chunguang, et al.
Publicado: (2012)

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin
por: Ueda, Yutaka, et al.
Publicado: (2010)

Paclitaxel, Carboplatin, and Bevacizumab in Advanced Cervical Cancer: A Treatment Response and Safety Analysis
por: Tao, Wanjun, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy
por: Roskies, M., et al.
Publicado: (2016)

Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab
por: Fukase, Mika, et al.
Publicado: (2020)

High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Chauffert, Bruno, et al.
Publicado: (2023)

Survivin expression in oral squamous cell carcinoma
por: Muzio, L Lo, et al.
Publicado: (2003)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel
por: Egawa, Takashi, et al.
Publicado: (2021)

Long-term recurrence-free survival of a patient with advanced pure primary ovarian squamous cell carcinoma treated with dose-dense paclitaxel combined with carboplatin
por: Yazawa, Hiroyuki, et al.
Publicado: (2017)

Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis
por: Ma, Yuhua, et al.
Publicado: (2017)

Significance of intracellular localization of survivin in cervical squamous cell lesions: Correlation with disease progression
por: KIM, SOO-AH, et al.
Publicado: (2014)

Survivin-Based Treatment Strategies for Squamous Cell Carcinoma
por: Santarelli, Andrea, et al.
Publicado: (2018)

Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel
por: Avelino, Camila Uanne Resende, et al.
Publicado: (2015)

Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel
por: Neil, Alexander J., et al.
Publicado: (2023)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
por: Chen, Yingkai, et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Increased RIPK4 expression is associated with progression and poor prognosis in cervical squamous cell carcinoma patients
por: Liu, De-Qing, et al.
Publicado: (2015)

Inverse expression of survivin and reprimo correlates with poor patient prognosis in gastric cancer
por: Cerda-Opazo, Paulina, et al.
Publicado: (2018)

Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma
por: Fujiwara, Kazuko, et al.
Publicado: (2011)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tke4mqega81n3jjklgna133qa3